On March 26, 2025, Aikang Medical released its 2024 annual performance announcement.

# Financial Report Data

• The promotion of the volume-based procurement policy: accelerating import substitution, the demand for surgical procedures continues to grow, and the sales of products within the volume-based procurement system further increase.
• Market expansion and digital orthopedics full-process solutions drive significant growth in overseas surgical volume and revenue.
• Product performance: Sales of hip and knee joint implants performed outstandingly, with revenue increasing by 25.8% year-on-year; revenue from spine and trauma implants saw a slight growth of 3.3%; revenue from digital orthopedic customized products and services experienced a stable growth of approximately 3.5%.
   

• Stock Performance: As of the morning of March 27, 2025, the share price of Aier Ophthalmology rose more than 8%, reaching HKD 6.10.
• Investment banks generally give Aikang Medical an outperform rating, with a target average price of HKD 6.59.

• Orthopedic implants: Aikang Medical's core products include hip and knee joint implants, as well as spinal and trauma implants. In 2024, the hip and knee joint implant business revenue increased by 25.8% year-on-year, demonstrating outstanding performance.
• Digital Orthopedics: The company possesses advanced iBot hip and knee surgical robots, which were approved in China in November 2023 and April 2024, respectively. Additionally, AK Medical offers a Visualized Intelligent Assistance System (VTS), utilizing 3D surgical intelligent planning software to preoperatively design the optimal surgical plan and achieve full-process visualization and real-time tracking during the procedure.
• Personalized Customization Services: Aikang Medical is one of the earliest companies globally to offer orthopedic personalized customization technical services. It pioneered the comprehensive orthopedic personalized diagnosis and treatment technology (ICOS), providing patients with personalized surgical planning solutions.
• 3D Printing Technology: AK Medical is at an international advanced level in metal additive manufacturing technology. By integrating this technology with clinical imaging data, it precisely constructs bone-like trabecular structures (3D ACT), providing more accurate solutions for orthopedic surgeries.
   

• Domestic market share: Aikang Medical is a leading enterprise in the field of artificial joints in China, with the highest market share in the domestic market.
• Overseas market expansion: The company's products have been widely used in more than 6,000 medical institutions across more than 30 countries and regions worldwide, with overseas revenue continuing to grow. Aikang Medical adopts a "Aikang + JRI" dual-brand strategy, highlighting the advantages of cost-effectiveness and stable product quality.